MA47594A - Utilisation de biomarqueurs dans l'identification de patients atteints d'un cancer sensibles à un traitement avec un inhibiteur de prmt5 - Google Patents
Utilisation de biomarqueurs dans l'identification de patients atteints d'un cancer sensibles à un traitement avec un inhibiteur de prmt5Info
- Publication number
- MA47594A MA47594A MA047594A MA47594A MA47594A MA 47594 A MA47594 A MA 47594A MA 047594 A MA047594 A MA 047594A MA 47594 A MA47594 A MA 47594A MA 47594 A MA47594 A MA 47594A
- Authority
- MA
- Morocco
- Prior art keywords
- biomarkers
- treatment
- identifying patients
- prmt5 inhibitor
- cancer sensitive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Primary Health Care (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762464006P | 2017-02-27 | 2017-02-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA47594A true MA47594A (fr) | 2020-01-01 |
Family
ID=61563368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA047594A MA47594A (fr) | 2017-02-27 | 2018-02-26 | Utilisation de biomarqueurs dans l'identification de patients atteints d'un cancer sensibles à un traitement avec un inhibiteur de prmt5 |
Country Status (22)
Country | Link |
---|---|
US (2) | US11279970B2 (fr) |
EP (1) | EP3585904B1 (fr) |
JP (1) | JP7225106B2 (fr) |
KR (1) | KR102573149B1 (fr) |
CN (1) | CN110382707A (fr) |
AU (1) | AU2018225312B2 (fr) |
BR (1) | BR112019017466A2 (fr) |
CA (1) | CA3049739A1 (fr) |
CL (1) | CL2019002438A1 (fr) |
CO (1) | CO2019008390A2 (fr) |
EA (1) | EA201992026A1 (fr) |
IL (1) | IL268842A (fr) |
JO (1) | JOP20190199B1 (fr) |
MA (1) | MA47594A (fr) |
MX (1) | MX2019010150A (fr) |
MY (1) | MY195860A (fr) |
PE (1) | PE20191359A1 (fr) |
PH (1) | PH12019501942A1 (fr) |
SG (1) | SG11201907607VA (fr) |
TN (1) | TN2019000212A1 (fr) |
UA (1) | UA127679C2 (fr) |
WO (1) | WO2018154104A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202321249A (zh) | 2015-08-26 | 2023-06-01 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
TN2018000310A1 (en) | 2016-03-10 | 2020-01-16 | Janssen Pharmaceutica Nv | Substituted nucleoside analogues for use as prmt5 inhibitors |
CN115626935A (zh) | 2016-10-03 | 2023-01-20 | 詹森药业有限公司 | 用作prmt5抑制剂的单环和双环系统取代的卡巴核苷类似物 |
JP7225106B2 (ja) | 2017-02-27 | 2023-02-20 | ヤンセン ファーマシューティカ エヌ.ベー. | Prmt5阻害剤による治療に応答する癌患者の同定におけるバイオマーカーの使用 |
WO2019112719A1 (fr) * | 2017-12-05 | 2019-06-13 | Angex Pharmaceutical, Inc. | Composés hétérocycliques en tant qu'inhibiteurs de prmt5 |
CN111479817B (zh) | 2017-12-08 | 2023-03-21 | 詹森药业有限公司 | 螺双环类似物 |
IL262658A (en) * | 2018-10-28 | 2020-04-30 | Memorial Sloan Kettering Cancer Center | Prevention of age related clonal hematopoiesis and diseases associated therewith |
CA3134613A1 (fr) | 2019-04-02 | 2020-10-08 | Aligos Therapeutics, Inc. | Composes ciblant prmt5 |
GB201905780D0 (en) | 2019-04-25 | 2019-06-05 | La Thangue Nicholas | Cancer therapy |
TW202112375A (zh) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | 使用prmt5抑制劑治療癌症之方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4224438A (en) | 1970-07-14 | 1980-09-23 | Boehringer Mannheim Gmbh | Adenosine-5'-carboxylic acid amides |
US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
CN1331326A (zh) * | 2000-06-30 | 2002-01-16 | 上海博德基因开发有限公司 | 一种新的多肽——人精氨酸甲基转移酶(hrmt)32.12和编码这种多肽的多核苷酸 |
AU2002351077A1 (en) | 2001-11-05 | 2003-05-19 | Exiqon A/S | Oligonucleotides modified with novel alpha-l-rna analogues |
US7034147B2 (en) | 2001-11-29 | 2006-04-25 | Irm Llc | Nucleoside analog libraries |
KR101032005B1 (ko) | 2002-02-19 | 2011-05-02 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 부분적이거나 완전한 a1 아데노신 수용체의 작용제 |
US20040043959A1 (en) | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
JPWO2005005450A1 (ja) | 2003-07-15 | 2006-08-24 | 三井化学株式会社 | 環状ビスジヌクレオチドの合成方法 |
CA2548283A1 (fr) | 2003-12-19 | 2005-07-21 | Koronis Pharmaceuticals, Inc. | Heterocycles mutagenes |
EP1844062A2 (fr) | 2005-01-21 | 2007-10-17 | Methylgene, Inc. | Inhibiteurs d'adn-methyltransferase |
US20110159111A1 (en) | 2006-06-29 | 2011-06-30 | Astex Therapeutics Limited | Pharmaceutical combinations |
US20080132525A1 (en) | 2006-12-04 | 2008-06-05 | Methylgene Inc. | Inhibitors of DNA Methyltransferase |
EP2342616A2 (fr) | 2008-09-23 | 2011-07-13 | Alnylam Pharmaceuticals Inc. | Modifications chimiques de monomères et d oligonucléotides par cycloaddition |
US8323918B2 (en) * | 2008-12-12 | 2012-12-04 | University Of South Carolina | Chloroacetamidine based inhibitors and activity based probes for the protein arginine methytransferases |
MX2012007026A (es) | 2009-12-18 | 2013-03-18 | Joslin Diabetes Center Inc | Compuestos que promueven la replicacion de celula beta y metodos de su uso. |
AU2011341441A1 (en) | 2010-12-03 | 2013-06-20 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
KR20130124959A (ko) | 2010-12-03 | 2013-11-15 | 에피자임, 인코포레이티드 | 히스톤 메틸전달효소의 7-데아자퓨린 조절제 및 그의 사용방법 |
EP2651885A1 (fr) | 2010-12-16 | 2013-10-23 | Abbvie Inc. | Composés antiviraux |
EP2694524B1 (fr) | 2011-04-04 | 2016-05-18 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Dérivés de 2'-o-aminooxyméthyl nucléoside pour l'utilisation dans la synthèse et la modification de nucléosides, nucléotides et oligonucléotides |
US20150057243A1 (en) | 2012-04-02 | 2015-02-26 | Northern University | Compositions and Methods for the Inhibition of Methyltransferases |
WO2014035140A2 (fr) | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Composés et compositions pour la modulation de l'activité histone méthyltransférase |
US20140100184A1 (en) | 2012-08-31 | 2014-04-10 | Baylor College Of Medicine | Selective inhibitors of histone methyltransferase dot1l |
CA2894126A1 (fr) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
SI2935222T1 (sl) | 2012-12-21 | 2019-02-28 | Epizyme Inc. | Inhibitorji PRMT5 in njihove uporabe |
US9745291B2 (en) | 2012-12-21 | 2017-08-29 | Epizyme, Inc. | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
WO2014100716A1 (fr) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
CA2935944A1 (fr) | 2014-01-09 | 2015-07-16 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Benzoxazine substituee et composes associes |
US20170198006A1 (en) | 2014-06-25 | 2017-07-13 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
EA034119B1 (ru) | 2014-07-01 | 2019-12-30 | Милленниум Фармасьютикалз, Инк. | Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента |
PE20171449A1 (es) | 2015-02-24 | 2017-10-02 | Pfizer | Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos |
TW202321249A (zh) | 2015-08-26 | 2023-06-01 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
KR20180116307A (ko) | 2016-03-10 | 2018-10-24 | 얀센 파마슈티카 엔.브이. | Prmt5 저해제로 사용하기 위한 치환 뉴클레오사이드 유사체 |
EA201990851A1 (ru) | 2017-02-24 | 2019-09-30 | Янссен Фармацевтика Нв | Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5 |
JP7225106B2 (ja) | 2017-02-27 | 2023-02-20 | ヤンセン ファーマシューティカ エヌ.ベー. | Prmt5阻害剤による治療に応答する癌患者の同定におけるバイオマーカーの使用 |
-
2018
- 2018-02-26 JP JP2019545251A patent/JP7225106B2/ja active Active
- 2018-02-26 MA MA047594A patent/MA47594A/fr unknown
- 2018-02-26 UA UAA201910005A patent/UA127679C2/uk unknown
- 2018-02-26 PE PE2019001538A patent/PE20191359A1/es unknown
- 2018-02-26 MX MX2019010150A patent/MX2019010150A/es unknown
- 2018-02-26 CN CN201880013998.5A patent/CN110382707A/zh active Pending
- 2018-02-26 TN TNP/2019/000212A patent/TN2019000212A1/en unknown
- 2018-02-26 US US16/487,852 patent/US11279970B2/en active Active
- 2018-02-26 CA CA3049739A patent/CA3049739A1/fr active Pending
- 2018-02-26 MY MYPI2019004748A patent/MY195860A/en unknown
- 2018-02-26 JO JOP/2019/0199A patent/JOP20190199B1/ar active
- 2018-02-26 EP EP18708634.3A patent/EP3585904B1/fr active Active
- 2018-02-26 BR BR112019017466-4A patent/BR112019017466A2/pt unknown
- 2018-02-26 EA EA201992026A patent/EA201992026A1/ru unknown
- 2018-02-26 AU AU2018225312A patent/AU2018225312B2/en active Active
- 2018-02-26 SG SG11201907607VA patent/SG11201907607VA/en unknown
- 2018-02-26 KR KR1020197024211A patent/KR102573149B1/ko active IP Right Grant
- 2018-02-26 WO PCT/EP2018/054644 patent/WO2018154104A1/fr active Application Filing
-
2019
- 2019-07-31 CO CONC2019/0008390A patent/CO2019008390A2/es unknown
- 2019-08-22 PH PH12019501942A patent/PH12019501942A1/en unknown
- 2019-08-22 IL IL26884219A patent/IL268842A/en unknown
- 2019-08-23 CL CL2019002438A patent/CL2019002438A1/es unknown
-
2022
- 2022-02-10 US US17/669,008 patent/US20220205026A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
SG11201907607VA (en) | 2019-09-27 |
EA201992026A1 (ru) | 2020-01-24 |
PH12019501942A1 (en) | 2020-06-29 |
US11279970B2 (en) | 2022-03-22 |
CL2019002438A1 (es) | 2019-11-29 |
TN2019000212A1 (en) | 2021-01-07 |
MX2019010150A (es) | 2019-10-21 |
EP3585904C0 (fr) | 2023-11-29 |
JP2020508048A (ja) | 2020-03-19 |
UA127679C2 (uk) | 2023-11-29 |
JOP20190199B1 (ar) | 2023-09-17 |
CA3049739A1 (fr) | 2018-08-30 |
AU2018225312A1 (en) | 2019-07-25 |
AU2018225312B2 (en) | 2024-02-08 |
KR102573149B1 (ko) | 2023-08-30 |
EP3585904A1 (fr) | 2020-01-01 |
JOP20190199A1 (ar) | 2019-08-27 |
KR20190122677A (ko) | 2019-10-30 |
US20220205026A1 (en) | 2022-06-30 |
WO2018154104A1 (fr) | 2018-08-30 |
BR112019017466A2 (pt) | 2020-03-31 |
EP3585904B1 (fr) | 2023-11-29 |
US20200010881A1 (en) | 2020-01-09 |
JP7225106B2 (ja) | 2023-02-20 |
MY195860A (en) | 2023-02-24 |
CO2019008390A2 (es) | 2019-08-20 |
PE20191359A1 (es) | 2019-10-01 |
IL268842A (en) | 2019-10-31 |
CN110382707A (zh) | 2019-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47594A (fr) | Utilisation de biomarqueurs dans l'identification de patients atteints d'un cancer sensibles à un traitement avec un inhibiteur de prmt5 | |
MA40761A (fr) | Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr | |
JP1631531S (ja) | 電子計算機 | |
MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA41117A (fr) | Imagerie d'un corps | |
MA46783A (fr) | Polythérapie de type thérapie cellulaire t et inhibiteur de btk | |
UA42295S (uk) | Комп'ютер | |
DK3283880T3 (da) | Prognostiske og diagnostiske glycan-baserede biomarkører af hjerneskade | |
MA54851A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA42409A (fr) | Oxystérols et leurs procédés d'utilisation | |
FR3044684B1 (fr) | Inhibiteurs de la corrosion vanadique a base d'yttrium et de magnesium | |
FR3032786B1 (fr) | Systeme de traitement de donnees et de modelisation pour l'analyse de la consommation energetique d'un site | |
IL281014A (en) | Detection and documentation of speeding violations | |
MA45865A (fr) | Procédés de détection et de traitement d'une tumeur exprimant pt346 pdk1 | |
FR3031641B1 (fr) | Procede d'identification d'une entite | |
DK3510341T3 (da) | Beskyttelsesbeklædningsenhed og anvendelse af denne | |
MA45573A (fr) | Anticorps anti-cd154 et procédés d'utilisation correspondant | |
FR3043811B1 (fr) | Procede d'identification d'une entite | |
UA42369S (uk) | Комп'ютер | |
MA50201A (fr) | Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants | |
MA50906A (fr) | Inhibiteurs d'immunoprotéasome | |
MA50887A (fr) | Tuyauterie résistante à la corrosion et procédés de fabrication et d'utilisation correspondants | |
IT201700041695A1 (it) | Apparato di misura bio-impedenziometrica di un paziente | |
FR3014353B1 (fr) | Dispositif de traitement d'un corps longiligne |